In 1986, shortly after the confirmation of BCR–ABL1 in CML [2], the first gene fusion involving an NTRK receptor was identified in a patient with colorectal cancer (Fig. 1). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.